ArticleThe Journal of experimental medicine2020
Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients.
Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.
- COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review.International journal of dermatology · 2022Pooled it
- A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.Nature communications · 2024Trial
- Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.PloS one · 2022Trial
- Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.International immunopharmacology · 2020Trial
- Review
- Plasticity of the infant immune system during the perinatal period.Nature reviews. Immunology · 2026Review
- Functional Profile of γδ T Cells in Severe and Moderate COVID-19: A Brazilian Cross-Sectional Study.Cells · 2026Article
- Article
- Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins.Research square · 2026Article
- Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.Frontiers in immunology · 2026Article
- Phenotypic Alterations of CD8+ and CD8- CD56+ NK Cell Subsets in Moderate and Severe COVID-19 Disease.Journal of immunology research · 2026Article
- Immune-Based Biomarkers as Predictors of Mortality in ECMO Therapy for Severe COVID-19 ARDS: Insights from a Retrospective Study.International journal of molecular sciences · 2025Observational
- Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- Circulating Mucosal-Associated Invariant T Cells Are Associated With Acute Human Ischemic Stroke and Predict Poor Outcome.Journal of the American Heart Association · 2025Article
- Persistent Immune Dysregulation during Post-Acute Sequelae of COVID-19 is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins.bioRxiv : the preprint server for biology · 2025Article
- Lipidomic signatures of ventilator-associated pneumonia in COVID-19 ARDS patients: a new frontier for diagnostic biomarkers.Annals of intensive care · 2025Article
- Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.Signal transduction and targeted therapy · 2025Review
- The Role of Mucosal-Associated Invariant T Cells in Viral Infections and Their Function in Vaccine Development.Vaccines · 2025Review
- Immune Checkpoint Receptor Expression Profiles of MAIT Cells in Moderate and Severe COVID-19.Scandinavian journal of immunology · 2025Article
- Riboflavin for women's health and emerging microbiome strategies.NPJ biofilms and microbiomes · 2024Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 includes lung infection ranging from mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key feature in ARDS pathophysiology. However, cellular actors involved in COVID-19-driven ARDS are poorly understood. Here, in blood and airways of severe COVID-19 patients, we serially analyzed unconventional T cells, a heterogeneous class of T lymphocytes (MAIT, γδT, and iNKT cells) with potent antimicrobial and regulatory functions. Circulating unconventional T cells of COVID-19 patients presented with a profound and persistent phenotypic alteration. In the airways, highly activated unconventional T cells were detected, suggesting a potential contribution in the regulation of local inflammation. Finally, expression of the CD69 activation marker on blood iNKT and MAIT cells of COVID-19 patients on admission was predictive of clinical course and disease severity. Thus, COVID-19 patients present with an altered unconventional T cell biology, and further investigations will be required to precisely assess their functions during SARS-CoV-2-driven ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.